I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Salubris (002294.SZ) announced that the company's subsidiary, Salubris (Suzhou) Pharmaceutical Co., Ltd., has submitted a listing application for its independently developed Class 1 biological drug "Takasimab Injection," which has been accepted by the National Medical Products Administration. The intended indications are: hypercholesterolemia and mixed dyslipidemia